Details
Zusammenfassung: <jats:title>Key Points</jats:title> <jats:p>Patient-specific pathways of resistance to venetoclax can be identified by high-content screening of clinical samples with a KI library. Sunitinib may overcome resistance to venetoclax for many patients by downregulating the expression of Bcl-xl, Mcl-1, and A1 in CLL cells.</jats:p>
Umfang: 934-947
ISSN: 0006-4971
1528-0020
DOI: 10.1182/blood-2015-12-687814